Pfizer granted accelerated OK for Xalkori in NSCLC ahead of schedule
This article was originally published in Scrip
With the speed in which the US FDA has been approving new cancer drugs and the fact that the agency has OK'd three new therapies targeted at the disease this month well ahead of schedule leaves one to wonder if the head of the oncology drugs office had promised his staff the remainder of the summer off if they put the pedal to the metal.
You may also be interested in...
Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.